Loading company
DiaMedica Therapeutics Inc.
DMAC · Nasdaq · ·
Next earnings: November 11, 2026
$8.22-1.4%Sep 29 close
- 1M
- +28.6%
- 6M
- +23.8%
- 1Y
- +19.7%
- 5Y
- +97.6%
DMAC · Nasdaq · ·
Next earnings: November 11, 2026
$8.22-1.4%Sep 29 close
DiaMedica Therapeutics Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$10.1M | -$7.7M | -31.69% |
| Profit per share | -$0.10 | -$0.23 | +56.52% |
| Free Cash Flow | -$8.1M | -$7.6M | -6.75% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
DiaMedica Therapeutics Inc. has no earnings call transcript available.
“With the recent positive interim results from Part 1a of our Phase 2 study evaluating DM199 in preeclampsia, we’re eager to continue advancement of this promising candidate to address ischemic diseases in the second half of this year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Fetal growth restriction (FGR) occurs when a fetus fails to reach its genetically determined growth potential in the womb, most commonly due to placental insufficiency. FGR affects an estimated 10% of pregnancies worldwide and is associated with significantly increased risks of stillbirth, preterm birth, and neonatal morbidity, as well as long-term neurodevelopmental, cardiovascular, and metabolic complications. In severe, early-onset cases, FGR often necessitates delivery before 32 weeks of gestation, when the risks of prematurity must be weighed against the dangers of continued growth restriction in utero. See the recently released white paper, “ The Potential of DM199 to Treat Fetal Growth Restriction ” .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from DiaMedica Therapeutics Inc.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.